Pacritinib-d4

SL-11192

Pacritinib-d4, >98%

Synonyms : SB1518-d4

IUPAC Name : (E)-44-(2-(Pyrrolidin-1-yl-2,2,5,5-d4)ethoxy)-6,11-dioxa-3-aza-2(4,2)-pyrimidina-1,4(1,3)-dibenzenacyclododecaphan-8-ene

Price And Availability
Pack Size	Price in USD	Add To Shopping Cart	Availability	Shipping Status
5MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
10MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
25MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
50MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026

Applications : Pacritinib-d4 is a deuterium labelled version of Pacritinib. This can be used as an analytical labelled reference standard. Pacritinib is an oral tyrosine kinase inhibitor that selectively targets Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3 (FLT3). It is currently being developed as a treatment option for intermediate and high risk myelofibrosis.

References : Hart S. et al.:Leukemia, 25(11), 1751-9, 2011; Hart S. et al.: Blood Cancer J. 1(11), e44, 2011; William A. D. et al.: J. Med. Chem., 54(13), 4638-58, 2011.

Storage : Keep container tightly closed under nitrogen or argon and refrigerate for long-term shelf life.

Caution : In case of contact with skin or eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing and gloves.